Menu Search
Equities

BIOTEST PRF

0N70:LSE

BIOTEST PRF

Actions
  • Price (EUR)27.49
  • Today's Change27.49 / --
  • Shares traded116.00
  • 1 Year change-11.31%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024 14:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

  • Revenue in EUR (TTM)707.00m
  • Net income in EUR68.50m
  • Incorporated2006
  • Employees2.46k
  • Location
    BIOTEST PRFLandsteinerstr. 5DREIEICH 63303GermanyDEU
  • Phone+49 61038010
  • Fax+49 6 103801150
  • Websitehttps://www.biotest.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.